El interés en corto de Tandem Diabetes Care da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tandem Diabetes Care. Los datos de interés en corto se actualizan cada dos semanas.

Tandem Diabetes Care (NASDAQ:TNDM) Bolsa, Informe de interés en corto

Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care Inc

News

Guidance

TNDM

Tandem Diabetes Sees FY24 Sales $903M-$910M Vs $890.982M Est

Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.42) by 16.67 percent. The company reported quarterly sales of $244.000 million which beat the analyst consensus estimate of $223.663 million by 9.09 percent. This is a 31.45 percent increase over sales of $185.622 million the same period last year.

Earnings

Earnings Beats

Tandem Diabetes Care Q3 2024 GAAP EPS $(0.35) Beats $(0.42) Estimate, Sales $244.000M Beat $223.663M Estimate

In the last three months, 5 analysts have published ratings on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $48.6, with a high estimate of $65.00 and a low estimate of $42.00. Surpassing the previous average price target of $45.00, the current average has increased by 8.0%.
<img src="https://www.benzinga.com/files/images/story/2024/1730901609_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tandem Diabetes Care. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tandem Diabetes Care's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>Unveiling the Story Behind Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Unraveling the Financial Story of Tandem Diabetes Care</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Tandem Diabetes Care's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.27% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Tandem Diabetes Care's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -12.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Tandem Diabetes Care's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.28%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.04, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 5 Experts

Bernstein analyst Lee Hambright initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Outperform rating and announces Price Target of $42.

Price Target

Initiation

Bernstein Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $42

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst David Roman initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral rating and announced a price target of $46. Tandem Diabetes Care shares fell 1.7% to close at $40.46 on Thursday. <a href="https://www.benzinga.com/quote/TNDM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Laura Prendergast initiated coverage on Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) with a Strong Buy rating and announced a price target of $18. Mural Oncology shares gained 2.6% to close at $3.20 on Thursday. <a href="https://www.benzinga.com/quote/MURA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst George Gianarikas initiated coverage on ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) with a Buy rating and announced a price target of $4.5. ASP Isotopes shares gained 11.1% to close at $3.01 on Thursday. <a href="https://www.benzinga.com/quote/ASPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller initiated coverage on Curbline Properties Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) with a Overweight rating and announced a price target of $25. Curbline Properties shares gained 4.3% to close at $22.60 on Thursday. <a href="https://www.benzinga.com/quote/CURB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Xiaopo Wei initiated coverage on MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) with a Buy rating and announced a price target of $26.8. MINISO Group shares fell 0.2% to close at $18.96 on Thursday. <a href="https://www.benzinga.com/quote/MNSO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MNSO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-1024x538.png" alt="" class="wp-image-580735" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11.png 1278w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

ASPI

CURB

MNSO

MURA

This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Goldman Sachs analyst David Roman initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral rating and announces Price Target of $46.

Goldman Sachs Initiates Coverage On Tandem Diabetes Care with Neutral Rating, Announces Price Target of $46

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
The company is also seeking deeper penetration within existing accounts through product innovations.
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
GLP-1 drugs such as Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide as Wegovy and Ozempic and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide as Zepbound and Mounjaro, have recently made waves.
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&amp;D initiatives.
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
Price Action: TNDM stock is down 0.37% at $40.92&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41146425/toyota-doubles-down-on-joby-aviation-500m-investment-powers-us-electric-air-taxi-certification-p" target="_blank" rel="noreferrer noopener">Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production</a>.</li>
</ul>

Health Care

General

Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says

RBC Capital analyst Shagun Singh initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Outperform rating and announces Price Target of $65.

RBC Capital Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $65

Analysts' ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $50.57, along with a high estimate of $58.00 and a low estimate of $39.00. Marking an increase of 7.14%, the current average surpasses the previous average price target of $47.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1727114409_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Tandem Diabetes Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Tandem Diabetes Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Tandem Diabetes Care's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 13.27%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tandem Diabetes Care's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -12.92%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.28%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 7 Ratings For Tandem Diabetes Care

Morgan Stanley analyst Patrick Wood maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight and maintains $45 price target.

Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target

Biotech

Tandem's t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin In The European Union

Morgan Stanley analyst Patrick Wood initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight rating and announces Price Target of $45.

Morgan Stanley Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $45

Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the app in March. Tandem encourages all impacted t:slim X2 iOS users to update their mobile app as soon as the new version is available in the Apple App Store.
Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin. There have been 143 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported.

AAPL

Tandem Diabetes Care Urges iOS Users to Update App to Prevent Insulin Pump Battery Issues

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VERV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.00</td>
<td>$121.2K</td>
<td>22</td>
<td>1.0K</td>
</tr>
<tr>
<td>GSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$41.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>913</td>
</tr>
<tr>
<td>CLOV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.00</td>
<td>$46.2K</td>
<td>7.3K</td>
<td>550</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>1.5K</td>
<td>183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$900.00</td>
<td>$56.1K</td>
<td>784</td>
<td>142</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$28.0K</td>
<td>3.4K</td>
<td>117</td>
</tr>
<tr>
<td>TNDM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$45.00</td>
<td>$26.4K</td>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$80.00</td>
<td>$32.0K</td>
<td>1.0K</td>
<td>52</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$72.50</td>
<td>$61.5K</td>
<td>8</td>
<td>46</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$550.00</td>
<td>$26.4K</td>
<td>184</td>
<td>26</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding VERV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), we observe a put option sweep with bullish sentiment. It expires in 186 day(s) on February 21, 2025. Parties traded 1000 contract(s) at a $5.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $121.2K, with a price of $120.0 per contract. There were 22 open contracts at this strike prior to today, and today 1005 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a call option sweep with bearish sentiment. It expires in 32 day(s) on September 20, 2024. Parties traded 200 contract(s) at a $41.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $140.0 per contract. There were 1865 open contracts at this strike prior to today, and today 913 contract(s) were bought and sold. 
• For CLOV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>), we notice a call option sweep that happens to be bearish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 350 contract(s) at a $2.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $46.2K, with a price of $132.0 per contract. There were 7304 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• For CRBP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), we notice a put option sweep that happens to be bullish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 38 contract(s) at a $50.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $1030.0 per contract. There were 1500 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 10 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $56.1K, with a price of $5617.0 per contract. There were 784 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3492 open contracts at this strike prior to today, and today 117 contract(s) were bought and sold. 
• For TNDM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), we notice a put option sweep that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 98 contract(s) at a $45.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $270.0 per contract. There were 10 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 50 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.0K, with a price of $640.0 per contract. There were 1099 open contracts at this strike prior to today, and today 52 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bullish, expiring in 214 day(s) on March 21, 2025. This event was a transfer of 42 contract(s) at a $72.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $61.5K, with a price of $1465.0 per contract. There were 8 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option trade that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 20 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $26.4K, with a price of $1320.0 per contract. There were 184 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ADMA

CLOV

CRBP

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

VERV

10 Health Care Stocks Whale Activity In Today's Session

This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March.
Notices were emailed to impacted customers on August 9, 2024 with updated information and recommendations for helping avoid pump battery depletion.
Tandem plans to release a new version of the app to address the remaining issues and will notify all users by email and app push notifications following its release.
Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin.&nbsp;here have been 107 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported.

Tandem Diabetes Care Update On March Recall Of t:connect Mobile App For iOS Devices; Says Under-delivery Of Insulin Because Of Pump Shutdown Can Be Life-threatening Condition

Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tandem Diabetes Care, presenting an average target of $57.18, a high estimate of $75.00, and a low estimate of $39.00. This upward trend is evident, with the current average reflecting a 17.49% increase from the previous average price target of $48.67.
<img src="https://www.benzinga.com/files/images/story/2024/1723132839_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Tandem Diabetes Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>All You Need to Know About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Tandem Diabetes Care's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 13.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tandem Diabetes Care's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -13.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tandem Diabetes Care's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.28%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is below the industry average at 2.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know

Canaccord Genuity analyst William Plovanic initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy rating and announces Price Target of $57.

Canaccord Genuity Initiates Coverage On Tandem Diabetes Care with Buy Rating, Announces Price Target of $57

WIIM

Tandem Diabetes Care shares are trading higher. The company last week reported better-than-expected Q2 earnings and issued strong guidance.

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $55 to $58.

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $58

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling more than 2% on Friday.
The Dow traded down 1.92% to 39,571.38 while the NASDAQ fell 2.56% to 16,754.04. The S&amp;P 500 also fell, dropping, 2.15% to 5,329.56.
Leading and Lagging Sectors Consumer staples shares rose by 0.3% on Friday.
In trading on Thursday, consumer discretionary shares dipped by 5.4%.
Top Headline
 Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) reported better-than-expected second-quarter FY24 results on Friday.
Total revenues and other income stood at $93.060 billion, beating the consensus of $90.987 billion. Adjusted net profit came in at $9.24 billion, up from $8.22 billion in the prior quarter. Adjusted EPS stood at $2.14, beating the consensus of $2.01.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares shot up 100% to $4.85 after the company announced an agreement with Ava Robotics to develop telepresence solutions for the inpatient intensive care market.</li>
<li>Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) got a boost, surging 37% to $0.6790&nbsp;after the company announced it received a continued listing determination from the Nasdaq.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares were also up, gaining 18% to $41.56 following better-than-expected second-quarter earnings and strong guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares dropped 29% to $1.68 after the company announced pricing of registered direct offering and concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million.</li>
<li>Shares of Gamer Pakistan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPAK#NASDAQ">GPAK</a>) were down 50% to $0.0845 after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Fresh Vine Wine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NASDAQ">VINE</a>) was down, falling 30% to $0.3051 after the company announced that it terminated the merger agreement with Notes Live.</li>
</ul>
Commodities In commodity news, oil traded down 3.9% to $73.37 while gold traded down 0.4% at $2,470.30.
Silver traded down 0.3% to $28.40 on Friday, while copper rose 0.6% to $4.1050.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 2.73%, Germany's DAX fell 2.33% and France's CAC 40 fell 1.61%. Spain's IBEX 35 Index fell 1.67%, while London's FTSE 100 fell 1.31%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 dipping 5.81%, Hong Kong's Hang Seng Index falling 2.08%, China's Shanghai Composite Index falling 0.92% and S&amp;P BSE Sensex declining 1.08%.
Economics
<ul>
<li>Nonfarm payrolls came in at 114,000 last month, a slowdown of 65,000 from June, and well below the economist consensus estimate of 175,000 according to TradingEconomics.</li>
<li>The unemployment rate rose from 4.1% to 4.3%, contrary to expectations of it remaining unchanged.</li>
<li>Wage growth showed further signs of cooling, with average hourly earnings rising by 0.2% month-over-month, down from 0.3% in June and slightly below expectations.</li>
<li>U.S. factory orders declined by 3.3% from the prior month to $564.2 billion in June compared to market estimates of a 2.9% drop.</li>
<li>The total number of active U.S. oil rigs were unchanged at 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40122820/amazon-apple-and-3-stocks-to-watch-heading-into-friday"> Amazon, Apple And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

BIAF

GPAK

VINE

VSEE

XCUR

Crude Oil Falls Sharply; Exxon Mobil Earnings Top Views

Stifel Nicolaus analyst Mathew Blackman maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target of $6...

Stifel Nicolaus Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)

The 1-Minute Market Report October 20, 2024

Tandem Diabetes Care Q3 2024 Earnings Preview

Bernstein initiated coverage of Tandem Diabetes (TNDM) with an Outperform rating and $42 price target The firm says innovation is driving accelerat...

Tandem Diabetes initiated with an Outperform at Bernstein

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Five Below downgraded, Snowflake upgraded: Wall Street's top analyst calls

Notable companies reporting after the market close, with earnings consensus, include Qualcomm (QCOM), consensus $2.56… ARM (ARM), consensus 26c… Gi...

Notable companies reporting after market close

Reports Q3 revenue $244.0M, consensus $223.7M. The company: "Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023. ...

Tandem Diabetes reports Q3 EPS (35c), consensus (40c)

FY 24 Non-GAAP gross margin is estimated to be approximately 51% and adjusted EBITDA margin is estimated to be breakeven as a percent of sales. Pub...

Tandem Diabetes sees FY24 revenue $903M-$910M, consensus $891M

Tandem Diabetes Care GAAP EPS of -$0.35 beats by $0.07, revenue of $243.97M beats by $19.85M

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

ACLS

ACTV

AFMC

AFSM

ARDT

ARKK

ASPN

AVUV

BAPR

BITO

BLOK

BMBL

BROS

CHRS

CPRX

CTVA

CVLT

DUOL

EMQQ

FIVE

FRSH

GILD

HUBS

IDRV

IVOO

IVOV

JETS

KCCA

KLAC

MAGS

MASI

MELI

MKSI

MSOS

MTCH

OSCR

PACS

PENG

PLAY

PODD

QCOM

RILY

RMBS

RRGB

RXRX

SEDG

SIVR

SMCI

SNOW

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SRPT

SSPY

SVAL

SYLD

TALO

TFIN

TMDV

TPHD

TPLC

TPSC

TRIP

TRUP

TTGT

TTWO

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

URNM

USMC

USMF

USVM

WOLF

Press Releases

Tandem Diabetes Care Announces Upcoming Conference Presentation

Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

Legal

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes Care Announces Upcoming Conference Participation

Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union

Tandem Diabetes Care to Announce Third Quarter 2024 Financial Results on November 6, 2024

Comments

Tandem Diabetes Care

Interés en corto

Tandem Diabetes Care (NASDAQ:TNDM) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL